| Acute myeloid leukemia (AML) |
|
R20076M HOVON 156 AML
AMLSG 28-18: Rimpiläinen
A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy.
|
| Acute myeloid leukemia (AML) |
|
R20052M
VenEx: Rimpiläinen
Two-Stage, Two-Arm, Open-Label Phase II Study of Venetoclax in Combination with Azacitidine in Acute Myeloid Leukemia Patients Selected Using Ex Vivo Drug Sensitivity Screening.
|
| Acute myeloid leukemia (AML) |
|
R21043M
HO150: Rimpiläinen
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
|
| Acute lymphoblastic leukemia (ALL) |
|
R20054M
ALLTogether: Rimpiläinen
ALLTogether1 – A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL). (Clinical phase 3).
|
|
Acute lymphoblastic leukemia (ALL)
|
|
R09080
NOPHO: Rimpiläinen
Treatment protocol for children (1.0 - 17.9 years of age) and young adults (18-45 years of age) with acute lymphoblastic leukemia. Phase III trial.
|
| Bladder cancer |
|
R19084M
Ca170-078: Moisander
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle- Invasive Bladder Cancer.
www.clinicaltrials.gov
|
| Bladder cancer |
|
R18164M
KEYNOTE-676: Tammela
A phase III, randomized, comparator-controlled clinical trial to study the efficacy and safety of Pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guerin (BCG) in participants with high-risk non-muscle invasive bladder cancer (HR NMIBC) that is persistent or recurrent following BCG induction.
www.clinicaltrials.gov
|
| Bladder cancer |
|
R15126M
WO29636 /Imvigor: Tammela
A phase III, open-label, multicenter, randomized study of MPDL3280A (ANTI-PD‑L1 ANTIBODY) versus observation as adjuvant therapy in patients with PD‑L1-Selected, high-risk muscle-invasive bladder cancer after cystectomy.
|
| Breast cancer |
|
R21064M
Kate3:Tanner
A randomized, multicenter, double-blind, placebo- controlled phase III study of the efficacy and safety of trastutsumab emtamsine in combination with atetsolizumab or placebo in positive locally advanced or metastatic breast cancer who have receideb prior trastuzumab (+/- pertuzumab)and taxane-based therapy (KATE3)
www.clinicaltrials.gov
|
| Breast cancer |
|
R21166M
GO42784, lidERA: Tanner
A phase III, randomized, open label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician`s Choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer
www.clinicaltrials.gov
|
| Breast cancer |
|
R21016M
AL-2001/IXABEPILONE: Tanner
Phase II, open label, single arm study to investigate anti-tumor effect of ixabepilone in patients with locally recurrent or metastatic breast cancer (mBC) selected by the ixabepilone Drug Response Prediction (DRP) after failure of an anthracycline and a taxane.
www.clinicaltrials.gov
|
| Breast cancer |
|
R16008M
BOLD: Tanner
A randomized phase III study comparing trastuzumab, pertuzumab,pertuzumab plus docetaxel followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2 positive breast cancer.
|
| Breast cancer |
|
R07195M
SOLD: Kellokumpu-Lehtinen
A randomized phase III study comparing trastuzumab plus docetaxel (HT) followed by 5FU, epirubicin, and cyclophosphamide (FEC) to the same regimen followed by single agent trastuzumab as adjuvant treatments for early breast cancer.
|
| Breast cancer |
|
R17078M
Monarch I3Y-MC-JPCF: Tiainen
A randomized, open-label, phase III study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, hormone positive, human epidermal receptor 2 negative breast cancer.
|
Breast cancer,
HER2 neg |
|
R21045M
AMEERA 5: Tanner
A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.
|
Breast cancer,
HER2 neg |
|
R18198M
Stesides: Tanner
Safety and pharmacokinetics of ODM-209 in patients with metastatic castration-resistant prostate cancer or estrogen receptorpositive, human epidermal growth factor receptor 2-negative advanced breast cancer.
|
Breast cancer,
HER2 neg |
|
R19038M
CLEE011A2207/Tanner
A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease.
|
Breast cancer,
HER2 neg |
|
R19083M
1280.18: Tanner
An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts.
|
Breast cancer,
HER2 neg, ER pos |
|
R200062M
Ca209-7FL: Tiainen
A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer.
www.clinicaltrials.gov
|
| Breast cancer, triple neg |
|
R18072M
MO39193/Impassion 132: Tanner
A phase III randomized, placebocontrolled multi-center study of the efficacy and safety of atezolizumab in combination with chemotherapy for patients with early relapsed triple-negative breast cancer.
|
| Breast cancer, triple neg |
|
R16132M
MK-3475-173 (KEYNOTE 173): Tanner
A phase 1b study to evaluate safety and clinical activity of pembrolizumab (MK-3475) in combination with chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) –
|
| Breast cancer |
|
R21142M:Tanner
An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)
www.clinicaltrials.gov
|
| Breast cancer |
|
R21137M
EPIK- B5/ CBYL719C2303: Tanner
A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor
www.clinicaltrials.gov
|
| Breast cancer |
|
R22104M
CBYL719G12301-EPIK-B2: Tanner
A two-part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess to efficacy and safety of Albelisib (BYL719)in combination with trastutzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation.
www.clinicaltrials.gov
|
| Cancer of Unknown Primary |
|
R18017M
CUPISCO MX39795: Tanner
A phase II, randomized, activecontrolled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have received three cycles of platinum doublet chemotherapy.
www.clinicaltrials.gov
|
| Cervical cancer |
|
R21138M
SGNTV-003:Auranen
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator´s Choice Chemotherapy in second or hird-Line Recurrent or Metastatic Cervical Cancer Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer.
www.clinicaltrials.gov
|
| CLL |
|
R19101M
ASSURE: Luopajärvi
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia.
|
| CLL |
|
R18015M
HO141 CLL: Luopajärvi
A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations.
|
| CLL |
|
R17047M
CLL13 GAIA: Luopajärvi
A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations.
|
| CLL |
|
R21145M
CLL17: Luopajärvi
A Phase 3 multicentre, randomized, prospective, open- label trial of Ibrutinib monotherapy versus fixed- duration Venetolax plus Obinutuzumab versus fixed- duration Venetolaclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL).
|
| Colorectal cancer |
|
R12116M
RAXO: Österlund
A population-based prospective study to evaluate clinical behaviour, resectability and survival in metastatic colorectal cancer patients in Finland.
|
| Colorectal cancer |
|
R12117M
AXOAXI: Salminen
Open-label, single-arm, phase II study of bevacizumab (AVASTIN) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer.
|
| Colorectal cancer |
|
R22001M
MIRATI-KRYSTAL: Salminen
A Randomized Phase 3 study of MRTX849 in Combination with cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression on or After Standard First-Line Therapy
www.clinicaltrials.gov
|
| Colorectal cancer |
|
R21151M
COLSTAR: Österlund
A Randomised, open-label, multi-cenre, two-arm Phase 3 study comparing futuximab/modotuximab in combination with trifluridine/tibiracil to trifluridine/tibiracil single agent with a Safety Lead-In part in participantsa with KRAS7NRAS and BRAF wild type metastatic colorectal cancer previously treated with standard treatment and anti EGFR therapy
www.clinicaltrials.gov
|
| Colorectal cancer |
|
R22069M
Breakwater C4221015: Salminen
An open-label, Multicenter, Randomized Phase 3 Study Of First-Line encorafenib Plus cetuximab With Or Without Chemoterapy Versus Standard Of Care Therapy With A Safety Lead-in Of encorafenib and cetuximab plus Chemoterapy In Participants With Metastatic BRAF V600E-Mutant Colorectal Cancer.
www.clinicaltrials.gov
|
| Endometrial cancer |
|
R21042M
MK3475-B21: Auranen
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053).
www.clinicaltrials.gov
|
| Endometrial cancer |
|
R19103M
RUBY: Auranen
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer.
|
| Endometrial cancer |
|
R16187M
PALEO: Auranen
A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus placebo in combination with Letrozole for patients with estrogen receptor positive advanced or recurrent endometrial cancer.
|
| Endometrial cancer |
|
EN2-DGCG: Auranen
Chemotherapy or observation in stage I-II intermediate or high risk endometrial cancer.
|
| Endometrial cancer |
|
R22019M
MK-3475-C93: Auranen
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair deficient (dMMR9 Advanced or Recurrent Endometrial Carcinoma in the Fisrt-line Settings (KEYNOTE-C93/GOG-3064/ENGOT-en15)
www.clinicaltrials.gov
|
| GIST |
|
R15127M
GIST SSGXXII: Paunu
Three versus five years of adjuvant Imatinib as treatment of patients with operable GIST with a high risk for recurrence: a randomised phase III multicenter study by the Scandinavian Sarcoma Group.
www.clinicaltrials.gov
|
| Head and neck carcinoma |
|
R15025M
MK-3475-048: Reinikainen
A phase III clinical trial of Pembrolizumab (MK-3475) in first line treatment of recurrent/ metastatic head and neck squamous cell carcinoma.
|
| Head and neck carcinoma |
|
R22015M
NANORAY-312: Skyttä, Lahtela
A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma.
www.clinicaltrials.gov
|
|
Leukemia
(AML, MDS, KMML)
|
|
R22065M
BEXMAB: Rimpiläinen
Study to Assess Safety, Tolerability and Preliminary Efficacy of the CLEVER-1 Antibody Bexmarilimab in Combination with Azacitidine or Azacitidine/Venetoclax in Patients with Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia.
|
| Liposarcoma |
|
R22060M
1403-0008: Lyly-Yrjänäinen
A Phase Ii/III, randomized, open -label, multi-center study of BI907828 compared to doxorubicin as first line treatment of patients with advanced dedifferential liposarcoma
www.clinicaltrials.gov
|
| Liver cancer |
|
R21105M
MO42541/Imbrave251: Österlund
A phase III, open-label, randomized study of atetzolizumab with lenvatinib or sarafenib versus lenvatinib or sorafenib alone in hepatocellular carsinoma previously treated with atetzolizumab and bevacizumab.
www.clinicaltrials.gov
|
| Lung cancer |
|
R19102M
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736): Skyttä
An open label randomized phase II trial with durvalumab following Stereotactic Body radiotherapy (SBRT) in patients with T1-2N0M0 Non-small Cell Lung Cancer (NSCLC).
www.clinicaltrials.gov
|
| Lung cancer |
|
R20069M
Apollomics INC APL-101-01: Ahvonen
Phase 1/2 Multicenter study of the safety, pharmacokinetics and preliminary efficacy of APL-101 in subjects with Non small Cell lung cancer with c-met EXON 14 skip mutations and c-Met dysregulation advanced solid tumors.
www.clinicaltrials.gov
|
| Lung cancer |
|
R20163M
DART: Ahvonen
Durvalumab (MEDI4736)after chemoradiotherapy (DART)for NSCLS patient- a phase II translational anb biomarker Study investigating PDL1 positive and negative patients.
www.clinicaltrials.gov
|
| Lung cancer |
|
R21079M
MK7684A-002: Ahvonen
A Phase 2, multicenter, randomized study to compare the efficacy and safety of MK-7684A or MK-7684A plus Docetaxel monotherapy in the treatment of participants with metastatic non-small cell lung cancer with progressive disease after treatment with a platinum douplet chemotherapy and immunotherapy.
|
| Lung cancer |
|
R22021M
MO43576/Imscin002: Ahvonen
A Randomized, multicenter, open-label cross-over study to evaluate participant and healthcare professional reported preference for subcutaneous atetzolizumab compared with intravenous atatsolizumab formulation in participants with non-small cell lung cancer.
www.clinicaltrials.gov
|
| Lung cancer |
|
R22017M
213824: Ahvonen
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer.
www.clinicaltrials.gov
|
| Lymphoma |
|
R18209M
FIORELLA: Pollari
Randomized phase II trial on Fitness and comorbidity- tailored treatment in elderly patents with newly diagnosed primary CNS lymphoma.
|
| Lymphoma |
|
R17145M
BIO-CHIC: Pollari
Biomarker driven and dose intensified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk diffuse large B-cell lymphoma (NLG-LBC-06).
|
| Lymphoma |
|
R18211M
SAKK: Pollari
Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial.
|
| Lymphoma |
|
R21062M
GENMAB3013-01: Pollari
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
www.clinicaltrials.gov
|
| Lymphoma |
|
R21117M
Hutchison-2018-532-00US1: Pollari
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary
Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma.
www.clinicaltrials.gov
|
| Lymphoma |
|
R21118M
Hutchison-2018-689-00US1: Pollari
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-689 in Patients with Relapsed or Refractory Lymphoma.
www.clinicaltrials.gov
|
|
Lymphoma
Diffuse Large B-cell Lymphoma
|
|
R21106M
MO40598, PolarGO: Pollari
A phase III, open label, multicenter, randomized study evaluating the safety and efficacy of polatuzumab vedotin in combination with rituximab plus gemsitabine plus oxaliplatin (R-GEMOX) versus R-GEMOX alone in patients with relapsed/refractory diffuse large B-cell lymphoma
www.clinicaltrials.gov
|
Lymphoma
Diffuse Large B-cell Lymphoma |
|
R16108M
MOR00208/B-MIND: Keskinen
A phase II/III, randomised, multicentre study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) who are not eligible for high-dose chemotherapy (HDC) and autologous stem-cell transplantation (ASCT) – B-MIND
|
Lymphoma
Diffuse Large B-cell Lymphoma |
|
R20119M
NLG-07 (POLAR BEAR): Pollari
R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years – an open label randomized Nordic Lymphoma Group phase III trial.
www.clinicaltrials.gov
|
Lymphoma
Diffuse Large B-cell Lymphoma |
|
R21080M
GCT3013-05: Pollari
A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma.
www.clinicaltrials.gov
|
Lymphoma
Non-Hodgkin |
|
R21082M
Genmab3013-02: Pollari
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma.
www.clinicaltrials.gov
|
Lymphoma
Non-Hodgkin |
|
R17032M
CHRONOS-4: Pollari
A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor Copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL)
|
|
Lymphoma
Mantle cell lymphoma
|
|
R19118M
ENRICH: Pollari
Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma.
|
| Lymphoma |
|
R21134M
InMIND(INCMOR0208-301): Pollari
A phase 3, randomized, double-blind, Placebo-controlled, multicenter Study to evaluate the efficacy and Safety of tafasitamab plus lenalidomide in addition to rituksimab versus lenalidomide in addition to rituksimab in patients with relapsed/refractory (R/R) Follicular lymphoma grade 1 to 3a or R/R marginal zone lymphoma.
www.clinicaltrials.gov
|
| Melanoma |
|
R13091M
Ca209-067: Skyttä
A Phase 3, randomized, double-blind study of Nivolumab monotherapy or Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in subjects with previously untreated unresectable or metastatic melanoma.
|
| Melanoma |
|
R15089M
CA209-238: Skyttä
A phase III, randomized, double-blind study of adjuvant immunotherapy with Nivolumab versus Ipilibumab after complete resection of st IIIb/c or st IV melanoma in subjects who are at high risk for recurrence.
|
| Melanoma |
|
R161334
MK3475-054 (KEYNOTE-054): Skyttä
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody MK-3475 versus placebo after complete resection of high-risk stage III melanoma: A randomized, double-blind phase 3 trial of the EORTC Melanoma Group.
|
| Melanoma |
|
R18084M
CA224-047: Skyttä
A randomized, double-blind phase II–III study of BMS-986016 combined with Nivolumab versus Nivolumab in participants with previously untreated metastatic or unresectable melanoma.
|
| Melanoma |
|
R19137M
CA209-76K / Skyttä
A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma.
|
| Melanoma |
|
R20134M
Nektar: Skyttä
A Phase 3, randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma.
|
| Melanoma |
|
R21152M
Ca224-098: Skyttä
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
www.clinicaltrials.gov
|
| Melanoma |
|
R22103M
Starboard C4221016: Skyttä
A Phase 3, randomized, double-blind study of encorafenib and binimetinib plus pembrolizumab versus placebo plus pembrolizumab in participants with BRAF V600E/K mutation-positive metastatic or unresectable locally advanced melanoma.
www.clinicaltrials.gov
|
| Myeloma |
|
R18039M
Myeloma: IRd NMSG 23/15: Sankelo
A prospective phase 2 study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients.
|
| Myeloma |
|
KeD: Sankelo
Phase 2 study of carfilzomib + elotuzumab +dexamethasone for relapsed or progressed multiple myeloma after 1-3 prior treatment lines.
|
| Myeloma |
|
R22064M
MAGNETISMM-5: Sankelo
An open-label, 3-arm, multicenter, randomized phase 3 study to evaluate the efficacy and safety of Elranatamab (PF-06863135) monotherapy and Elranatamab+Daratumumab versus Daratumumab+Pomalidomide+Dexamethasone in participants with relapsed/refractory multiple myeloma who have received at least 2 prior lines of therapy including lenalidomide and a proteasome inhibitor.
www.clinicaltrials.gov
|
| Osteosarcoma |
|
R20053M
OLIE: Palmu
A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficasy and safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma.
|
| Ovarian cancer |
|
R20048M
AGO-OVAR 2.29: Auranen
Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer- a randomized Phase III trial An ENGOT trial.
www.clinicaltrials.gov
|
| Ovarian cancer |
|
R17105M
IMagyn050: Auranen
A phase III, multicenter, randomized, study of Atezolizumab versus Plasebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab to patients with newly-diagnosed stage III or IV ovarian, fallopian tube, or primary peritoneal cancer.
|
| Ovarian cancer |
|
R16061M
AVANOVA: Auranen
Niraparib vs. niraparib-bevacizumab combination in women with platinum-sensitive epithelial ovarian, fallopian tube or peritoneal cancer. Phase II trial.
|
| Ovarian cancer |
|
R18152M
Tesaro FIRST: Auranen
A randomized, double-blind, phase 3 comparison of platinum-based therapy with TSR-042 and niraparib versus standard of care platinum-based therapy as first-line treatment of stage III or IV nonmucinous epithelial ovarian cancer.
|
| Ovarian cancer |
|
EWOC-1: Auranen
Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian cancer.
|
| Ovarian cancer |
|
R16064M
PAOLA: Mäenpää
Platinum, avastin and olaparib in first line treatment of patients with advanced ovarian/fallopian tube/peritoneal cancer. Phase III trial.
|
| Ovarian cancer |
|
R21131M
EPIK-O: Auranen
A Phase III, multi-center, randomized (1:1), open- label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer.
www.clinicaltrials.gov
|
| Ovarian cancer |
|
R22077M
DOVACC: Auranen
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer
www.clinicaltrials.gov
|
| Pancreatic adenocarcinoma |
|
R14070M
APACT: Salminen
A phase III, multicenter, open-label randomized study of NAB-PACLITAXEL plus GEMCITABINE alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma.
|
| Pancreatic adenocarcinoma |
|
R22058M
CNIS793B12301: Salminen
A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)
www.clinicaltrials.gov
|
| Prostate cancer |
|
R20107M
MK-3475-991: Jukkola
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
|
| Prostate cancer |
|
R18198M
Stesides: Tanner
Safety and pharmacokinetics of ODM-209 in patients with metastatic castration-resistant prostate cancer or estrogen receptorpositive, human epidermal growth factor receptor 2-negative advanced breast cancer.
|
| Prostate cancer |
|
R19098M
CYPIDES: Tanner
Safety and pharmacikinetics of ODM- 208 in patients with metastatic castration-resistant prostate cancer.
www.clinicaltrials.gov
|
| Prostate cancer |
|
R21123M
Talapro 3: Tammela
A phase 3, randomized, double-blind, study of Talazoparib with Enzalutamide versus placebo with Enzalutamide in men with DDR gene mutated metastatic castration-sensitive prostate cancer.
|
| Prostate cancer |
|
R19062M
Talapro-2: Tammela
A Phase 3 randomized double-blind placebo-controlled study of talazoparib in combination with enzalutamide in men with metastatic castration resistant prostate cancer.
|
| Prostate cancer |
|
R18020M
Astellas: Tammela
A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study.
|
|
Prostate cancer
|
|
R16033H
9785-CL-0403 Arches : Tammela
A multinational, phase III, randomized, double-blind, placebo-controlled efficacy and safety study of Enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC), protocol number 9785-CL-0335
|
|
Prostate cancer
|
|
R14009
ESKO: Reinikainen
Radiotherapy in prostate cancer
|
|
Prostate cancer
|
|
R16118M
ODX-003: Tammela
A randomised, double-blind, dose finding, repeat dose phase II multicentre study of ODX for the treatment of patients with castration-resistant prostate cancer (CRPC) and skeletal metastases.
|
|
Prostate cancer
|
|
R15062M
MDV3100-13 /Embark: Tammela
A phase III, randomized, efficacy and safety study of Enzalutamide plus Leuprolide, Enzalutamide monotherapy, and placebo plus Leuprolide in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy.
|
|
Prostate cancer
|
|
R14049M
Bayer 15396: Paunu
A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with Abiraterone acetate and Prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)
|
|
Prostate cancer
|
|
R06170M
AdRad: Kellokumpu-Lehtinen
A randomized adjuvant phase III trial of six cycles of Docetaxel+hormonal treatment versus hormonal treatment in patients with intermediate or high-risk prostate cancer treated with radical radiotherapy (SPCG-13)
|
| Prostate cancer |
|
R19120M
RhoVac/Tammela
A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate Cancer.
|
| Prostate cancer |
|
R20132M
Radiant:Tammela
A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH.
|
| Prostate cancer |
|
R20101M
Bayer ROS: Tammela
An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies.
|
| Renal Cell Carcinoma |
|
R21059M
MK-6482-012: Kankaanranta
An open-label, randomized phase 3 study to evaluate efficacy and safety of Pembrolizumab (MK-3475) in combination with Belzutifan (MK6482) and Lenvatinib (Mk7902) or MK-1308A in combination with Lenvatinib versus Pembrolizumab and Lenvatinib ad first- line treatment on participants with advanced clear renal cell carcinoma.
www.clinicaltrials.gov
|
| Renal Cell Carcinoma |
|
R19116M
EXELIXIS: Kankaanranta
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk.
|
| Renal Cell Carcinoma |
|
R21065M
Ca209-67T: Kankaanranta
A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy.
www.clinicaltrials.gov
|
| Renal Cell Carcinoma |
|
R15010M
Ca209-214:Kellokumpu-Lehtinen
A Phase 3, randomized, open-label study of Nivolumab combined with Ipilimumab versus Sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma.
|
|
Renal Cell Carcinoma
|
|
R17092M
KEYNOTE-564: Kankaanranta
A phase III, randomized, double-blind, placebo-controlled clinical trial of Pembrolizumab (MK-3475) as monotherapy in the adjuvant treatment of renal cell carcinoma post nephrectomy.
|
| Renal Cell Carcinoma |
|
R20039M
MK-6482-005: Pollari
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD- 1/L1 and VEGF-Targeted Therapiesx.
|
| Renal Cell Carcinoma |
|
R22034M
MK-6482-022: Kankaanranta
A Multi-center, Double-Blind, Randomized Phase 3 study to Compare the Efficacy and Safety Beltuzifan(MK-6482) plus Pembrolizumab (MK-3475) Verusu Palcebo plus Pembrolizumab, in the Adjuvant Treatment of clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy( 6482-022)
www.clinicaltrials.gov
|
| Renal Cell Carcinoma |
|
R21063M
MK-6482-011: Kankaanranta
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
www.clinicaltrials.gov
|
| Solid tumors |
|
R21153M
INCB 99318-122: Tanner
A phase I study exploring the safety, tolerability, pharmacokinetics and pharmacodynamics of INCB099318 in participants with select advanced solid tumors
www.clinicaltrials.gov
|
| Solid tumors |
|
R19126M
MATINS: Mäenpää, Skyttä, Tanner
A Phase I/II Open–Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects with Advanced Solid Tumours.
www.clinicaltrials.gov
|
|
Platinum-resistant serous ovarian cancer
|
|
R21109M
Mersana: Auranen
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b.
www.clinicaltrials.gov
|
| Urothelial carcinoma |
|
R18095M
BAY 1163877: Kellokumpu-Lehtinen & Sormunen
A randomized, open label, multicenter Phase II-III study to evaluate the efficacy and safety of rogaratinib (BAY 163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinumcontaining chemotherapy.
|
|
|
R18212M
Bayer 16996: Tanner
A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride.
|
|
|
R22012M
FINPROVE: Tanner, Auranen
The Finnish National Study to Facilitate Patient Access to Targeted Anti-Cancer Drugs to determine the Efficacy in Treatment of Advanced Cancer with a Known Molecular Profile
www.clinicaltrials.gov
|